Moreover, the association of TMZ and targeted therapies, as anti-VEGF factors (bevacizumab) or mTOR inhibitors (everolimus) were used in aggressive pituitary carcinomas, even if with limited data and efficacy [46–49], but to date no cases have been described in patients with CTP-BADX/NS. This evidence concerns the gene VEGFA and pituitary adenocarcinoma.